Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jun;241(6):1177-1190.
doi: 10.1007/s00213-024-06551-7. Epub 2024 Feb 15.

Effects of arginine vasopressin on human anxiety and associations with sex, dose, and V1a-receptor genotype

R R Thompson  1   2 , D Price  3 , D Burris  3 , A Cloutier  3 , J K Rilling  4   5   6   7   8
Affiliations
Randomized Controlled Trial

Effects of arginine vasopressin on human anxiety and associations with sex, dose, and V1a-receptor genotype

R R Thompson et al. Psychopharmacology (Berl). 2024 Jun.

Abstract

Rationale: Arginine vasopressin (AVP) has dose- and sex-specific effects on social behavior, and variation in social responses is related to variation in the V1a receptor gene in animals. Whether such complexity also characterizes AVP effects on anxiety in humans, or whether V1a genotype is related to anxiety and/or AVP's ability to affect it, remains to be determined.

Objective: To test if AVP has dose-dependent effects on anxiety in men and/or women and if a particular allele within the RS3 promoter region of the V1a receptor gene is associated with anxiety and/or AVP effects on anxiety.

Method: Men and women self-administered 20 IU or 40 IU intranasal arginine vasopressin (AVP) and placebo in a double-blind, within-subjects design, and State (SA) and Trait (TA) anxiety were measured 60 min later. PCR was used to identify allelic variation within the RS3 region of the V1a receptor gene.

Results: AVP decreased SA in men across both doses, whereas only the lower dose had the same effect, across sexes, in individuals who carry at least one copy of a previously identified "risk" allele in the RS3 promoter of the V1a receptor gene. Additionally, after placebo, women who carried a copy of the allele displayed lower TA than women who did not, and AVP acutely increased TA scores in those women.

Conclusions: Exogenous AVP has modest sex- and dose-dependent effects on anxiety/affect in humans. Further, allelic variation in the V1a promoter appears associated with responsiveness to AVP's effects and, at least in women, to stable levels of anxiety/affect.

Keywords: Context; Intranasal; RS3; State anxiety; Trait anxiety.

PubMed Disclaimer

References

    1. Albers HE (2015) Species, sex and individual differences in the vasotocin/vasopressin system: relationship to neurochemical signaling in the social behavior neural network. Front Neuroendocrinol 36:49–71 - PubMed - DOI
    1. Avinun R, Israel S, Shalev I, Gritsenko I, Bornstein G, Ebstein RP et al (2011) AVPR1A variant associated with preschoolers’ lower altruistic behavior. PLoS One 6(9):e25274 - PubMed - PMC - DOI
    1. Avinun R, Ebstein RP, Knafo A (2012) Human maternal behaviour is associated with arginine vasopressin receptor 1A gene. Biol Lett 8(5):894–896 - PubMed - PMC - DOI
    1. Balsamo M, Romanelli R, Innamoratti M, Ciccarese G, Carlucci L, Saggino A (2013) The State-Trait Anxiety Inventory: shadows and lights on its construct validity. J Psychopathol Behav Assess 35:475–486 - DOI
    1. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K et al (1994) Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 151(8):1132–1136 - PubMed - DOI

Publication types

Substances